Interstitial Lung Disease Clinical Trial Drug Development Pipeline Expands With Contributions From 120+ Key Companies Delveinsight
(Albany, US), September 10, 2026- DelveInsight's“ Interstitial Lung Diseases Pipeline Insight 2026” report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in the Interstitial Lung Disease pipeline landscape. It covers the Interstitial Lung Diseases pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Interstitial Lung Diseases pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Interstitial Lung Diseases Pipeline @
Key Takeaways from the Interstitial Lung Diseases Pipeline Report
-
On September 08, 2026, Tectonic Operating Company Inc. conducted a study is to assess the effect of TX000045 on pulmonary vascular resistance (PVR) in participants with pulmonary hypertension secondary to interstitial lung disease (PH-ILD) and to assess the safety and tolerability of TX000045 in participants with PH-ILD.
On September 08, 2026- Boehringer Ingelheim highlighted a study is to find out how a medicine called nerandomilast affects the lungs in people with systemic autoimmune rheumatic disease.
On September 08, 2026- GlaxoSmithKline organized a phase 3 study will assess whether treatment of CTD-ILD participants with belimumab in addition to standard therapy will result in the stabilization and/or improvement of lung function and improve symptoms associated with ILD with an acceptable safety profile.
On September 02, 2026- Pulmovant Inc. initiated a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.
DelveInsight's Interstitial Lung Diseases Pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for Interstitial Lung Diseases treatment.
The leading Interstitial Lung Diseases Companies such as Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences and others.
Promising Interstitial Lung Diseases Pipeline Therapies such as Dotarem, efzofitimod 450 mg, Fentanyl Citrate, Belimumab, Nintedanib (Ofev®), Anlotinib, Pirfenidone, BI 1015550, Bosentan, Mycophenolate mofetil, Cyclophosphamide and others.
Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Interstitial Lung Diseases Treatment Drugs
Interstitial Lung Disease Overview
Interstitial lung disease (diffused parenchymal diseases) are a heterogeneous group of disorders characterized by fibrosis (scarring) of the lungs. These are classified on the basis of histopathological, radiologic and clinical parameters. The classification system used to describe interstitial lung disease categorizes conditions based on clinical, histopathological or radiologic parameters. Clinical classification groups ILD by its causes to help differentiate exogenous or endogenous factors. Interstitial lung disease diseases without identifiable causes get grouped under idiopathic/primary which uses the histopathological and radiological approach as its infrastructure. Many of the subsets of the disease are of unknown etiology. Regardless, they all ultimately share the same manner of development. The morphological changes seen histologically result from a sequence of inflammation within the parenchyma, which is the portion of the lung involved in gas exchange (the alveoli, the alveolar ducts, and the bronchioles). This compartment is the habitat to various proteins and pro-fibrotic elements. These proteins, after repeated cycles of activation, give rise to accumulation of connective tissue. The trigger can be a known agent that deposited within the lung tissues. In some cases, the fibrosis arises spontaneously
Interstitial Lung Diseases Emerging Drugs Profile
-
DWN12088: Daewoong Pharmaceutical
DWN12088 is an investigational therapy for idiopathic Interstitial Lung Diseases (IPF), that has shown the promising anti-fibrotic properties and appeared to be safe and well-tolerated in a recently-completed Phase I clinical trial that enrolled healthy volunteers. DWN12088 is an investigational IPF therapy that limits the body's ability to produce collagen by preventing an enzyme called glutamyl-prolyl-tRNA synthetase from adding proline to the protein's sequence. The FDA designated it as an orphan drug for idiopathic Interstitial Lung Diseases (IPF) in 2019. The drug is currently in Phase II stage of clinical trial evaluation to treat IPF.
-
LYT-100: PureTech
LYT-100 is PureTech's most advanced wholly-owned therapeutic candidate. A deuterated form of pirfenidone, an approved anti-inflammatory and anti-fibrotic drug, LYT-100 is being advanced for the potential treatment of conditions involving inflammation and fibrosis, including lung disease (e.g., IPF and potentially other PF-ILDs and Long COVID respiratory complications and related sequelae), and disorders of lymphatic flow, such as lymphedema. PureTech completed a Phase 1 multiple ascending dose and food effect study evaluating LYT-100 in healthy volunteers and found it to be well-tolerated at all doses tested. PureTech is evaluating LYT-100 in a Phase 2 trial as a potential treatment for Long COVID respiratory complications and related sequelae as well as in a Phase 2a proof-of-concept study in patients with breast cancer-related, upper limb secondary lymphedema. PureTech is also advancing LYT-100 for the treatment of IPF and potentially other PF-ILDs and is planning registration-enabling studies. PureTech also expects to initiate a Phase 2 dose-ranging trial of LYT-100 in patients with IPF in the first half of 2022.
-
BMS-986278: Bristol-Myers Squibb
BMS 986278, a lysophosphatidic acid receptor antagonist (LPA1) is being developed by Bristol-Myers Squibb, the treatment of idiopathic Interstitial Lung Diseases. BMS-986278 is a potent and complete antagonist of LPA action at LPA1-mediated Gi, Gq, G12, and β-arrestin signaling pathways in both cells heterologously expressing human LPA1 and in primary human lung fibroblasts. Currently, it is in Phase II stage of clinical trial evaluation.
The Interstitial Lung Diseases Pipeline Report Provides Insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Interstitial Lung Diseases with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Interstitial Lung Diseases Treatment.
Interstitial Lung Diseases Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Interstitial Lung Diseases Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Interstitial Lung Diseases market
Explore groundbreaking therapies and clinical trials in the Interstitial Lung Diseases Pipeline @ New Interstitial Lung Diseases Drugs
Interstitial Lung Diseases Companies
Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences and others.
Interstitial Lung Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Oral
Intravenous
Subcutaneous
Interstitial Lung Diseases Products have been categorized under various Molecule types such as
-
Small molecule
Cell Therapy
Peptides
Polymer
Small molecule
Gene therapy
Unveil the future of Interstitial Lung Diseases Treatment @ Interstitial Lung Diseases Market Drivers and Barriers
Scope of the Interstitial Lung Diseases Pipeline Report
-
Coverage- Global
Interstitial Lung Diseases Companies- Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences and others.
Interstitial Lung Diseases Pipeline Therapies- Dotarem, efzofitimod 450 mg, Fentanyl Citrate, Belimumab, Nintedanib (Ofev®), Anlotinib, Pirfenidone, BI 1015550, Bosentan, Mycophenolate mofetil, Cyclophosphamide and others.
Interstitial Lung Diseases Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Interstitial Lung Diseases Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Interstitial Lung Diseases Therapies and clinical trials @ Interstitial Lung Diseases Companies, Key Products and Unmet Needs
Table of Contents
Introduction Executive Summary Interstitial Lung Disease: Overview Pipeline Therapeutics Therapeutic Assessment Interstitial Lung Disease– DelveInsight's Analytical Perspective Late Stage Products (Phase III) RO-0220912: Roche Drug profiles in the detailed report..... Mid Stage Products (Phase II) Daratumumab: Janssen Biotech Drug profiles in the detailed report..... Early Stage Products (Phase I) BGB 16673: BeiGene Drug profiles in the detailed report..... Preclinical Stage Products Drug name: Company name Inactive Products Interstitial Lung Disease Key Companies Interstitial Lung Disease Key Products Interstitial Lung Disease- Unmet Needs Interstitial Lung Disease- Market Drivers and Barriers Interstitial Lung Disease- Future Perspectives and Conclusion Interstitial Lung Disease Analyst Views Interstitial Lung Disease Key Companies AppendixAbout Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment